Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: Implications for age-related degenerative diseases of the eye

Cytokine

Volumn 62, Issue 3, 2013, Pages 369-381

  Lin, Tony ^a   Walker, Gregory Brett ^b   Kurji, Khaliq ^c   Fang, Edward ^b   Law, Geoffrey ^b   Prasad, Shiv S ^d   Kojic, Luba ^b   Cao, Sijia ^b   White, Valerie ^b   Cui, Jing Z ^b   Matsubara, Joanne A ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d HEALTH CANADA   (Canada)

Author keywords

Age related macular degeneration; CXCL11; Microarray; Pathway analysis; Vitreous

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CASPASE 10; CASPASE 2; CASPASE 3; CASPASE 4; CASPASE 6; CASPASE 7; CXCL11 CHEMOKINE; CYTOCHROME C; CYTOKERATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; INTERLEUKIN 8; INTERLEUKIN 9; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RANTES; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN; CXCL11 PROTEIN, HUMAN; KERATIN; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ARTICLE; CCL5 GENE; CELL VIABILITY; CONTROLLED STUDY; CXCL11 GENE; CYTOKINE RELEASE; DOWN REGULATION; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREACTIVITY; IP10 GENE; MX1 GENE; MX2 GENE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; RPE GENE; RSAD2 GENE; UNINDEXED SEQUENCE; UPREGULATION; ANALOGS AND DERIVATIVES; CELL CULTURE; CELL SURVIVAL; COMPLICATION; DONOR; DRUG EFFECTS; DRUSEN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; POSTMORTEM CHANGE; REPRODUCIBILITY;

CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CXCL11; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; KERATINS; LYSINE; MACULAR DEGENERATION; PIGMENT EPITHELIUM OF EYE; POSTMORTEM CHANGES; REPRODUCIBILITY OF RESULTS; RETINAL DRUSEN; SERUM ALBUMIN, BOVINE; TISSUE DONORS; UP-REGULATION;

EID: 84877804396     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.027     Document Type: Article

References (66)

1. Bressler NM., Bressler S.B., Congdon N.G., Ferris F.L., Friedman D.S., Klein R., et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003, 121:1621-1624.
2. Anderson D.H., Mullins R.F., Hageman G.S., Johnson L.V. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002, 134:411-431.
3. Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA 2005, 102:7053-7054.
4. Johnson L.V., Leitner W.P., Rivest A.J., Staples M.K., Radeke M.J., Anderson D.H. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002, 99:11830-11835.
5. Mullins R.F., Russell S.R., Anderson D.H., Hageman G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000, 14:835-846.
6. Glenn J.V., Stitt A.W. The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta 2009, 1790:1109-1116.
7. McFarlane S., Glenn J.V., Lichanska A.M., Simpson D.A., Stitt A.W. Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium. Br J Ophthalmol 2005, 89:107-112.
8. Tian J., Ishibashi K., Reiser K., Grebe R., Biswal S., Gehlbach P., et al. Advanced glycation endproduct-induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response. Proc Natl Acad Sci USA 2005, 102:11846-11851.
9. Glenn J.V., Mahaffy H., Wu K., Smith G., Nagai R., Simpson D.A., et al. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci 2009, 50:441-451.
10. Honda S., Farboud B., Hjelmeland L.M., Handa J.T. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation end products in vitro. Invest Ophthalmol Vis Sci 2001, 42:2419-2425.
11. Kurji K.H., Cui J.Z., Lin T., Harriman D., Prasad S.S., Kojic L., et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010, 51:1151-1163.
12. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001, 20:705-732.
13. de Arriba S.G., Loske C., Meiners I., Fleischer G., Lobisch M., Wessel K., et al. Advanced glycation endproducts induce changes in glucose consumption, lactate production, and ATP levels in SH-SY5Y neuroblastoma cells by a redox-sensitive mechanism. J Cereb Blood Flow Metab 2003, 23:1307-1313.
14. Farboud B., Aotaki-Keen A., Miyata T., Hjelmeland L.M., Handa J.T. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Mol Vis 1999, 5:11.
15. Min C., Kang E., Yu S.H., Shinn S.H., Kim Y.S. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999, 46:197-202.
16. Sakata N., Meng J., Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000, 7:169-176.
17. Verbeke P., Perichon M., Friguet B., Bakala H. Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells. Biochim Biophys Acta 2000, 1502:481-494.
18. Yamagishi S., Adachi H., Takeuchi M., Enomoto M., Furuki K., Matsui T., et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007, 39:845-848.
19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
20. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
21. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
22. Du Yan S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997, 94:5296-5301.
23. Lue L.F., Yan S.D., Stern D.M., Walker D.G. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005, 4:249-266.
24. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000, 28:1708-1716.
25. Harja E., Bu D.X., Hudson B.I., Chang J.S., Shen X., Hallam K., et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008, 118:183-194.
26. Gul A., Rahman M.A., Hasnain S.N. Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients. Graefes Arch Clin Exp Ophthalmol 2009, 247:809-814.
27. Zieman S.J., Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004, 64:459-470.
28. Muller M., Carter S., Hofer M.J., Campbell I.L. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010, 36:368-387.
29. Cao X., Shen D., Patel M.M., Tuo J., Johnson T.M., Olsen T.W., et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int 2011, 61:528-535.
30. Jiang K., To E., Cui J.Z., Cao S., Gao J., Matsubara J.A. Drusen and pro-inflammatory mediators in the post-mortem human eye. J Clin Exp Ophthalmol 2012, 3:208.
31. Olofsson P.S., Jatta K., Wagsater D., Gredmark S., Hedin U., Paulsson-Berne G., et al. The antiviral cytomegalovirus inducible gene 5/viperin is expressed in atherosclerosis and regulated by proinflammatory agents. Arterioscler Thromb Vasc Biol 2005, 25:e113-e116.
32. Kim Y.H., He S., Kase S., Kitamura M., Ryan S.J., Hinton D.R. Regulated secretion of complement factor H by RPE and its role in RPE migration. Graefe's Arch Clin Exp Ophthalmol [Albrecht von Graefes Arch Klin Exp Ophthalmol] 2009, 247:651-659.
33. Nagineni C.N., Detrick B., Hooks J.J. Synergistic effects of gamma interferon on inflammatory mediators that induce interleukin-6 gene expression and secretion by human retinal pigment epithelial cells. Clin Diagn Lab Immunol 1994, 1:569-577.
34. Wu Z., Lauer T.W., Sick A., Hackett S.F., Campochiaro P.A. Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. JBC 2007, 282:22414-22425.
35. Arnold J., Grune T. PARP-mediated proteasome activation: a co-ordination of DNA repair and protein degradation?. Bioessays 2002, 24:1060-1065.
36. Ethen C.M., Hussong S.A., Reilly C., Feng X., Olsen T.W., Ferrington D.A. Transformation of the proteasome with age-related macular degeneration. FEBS Lett 2007, 581:885-890.
37. Hussong S.A., Kapphahn R.J., Phillips S.L., Maldonado M., Ferrington D.A. Immunoproteasome deficiency alters retinal proteasome's response to stress. J Neurochem 2010, 113:1481-1490.
38. Mo F.M., Proia A.D., Johnson W.H., Cyr D., Lashkari K. Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010, 51:4226-4236.
39. Detrick B., Hooks J.J. Immune regulation in the retina. Immunol Res 2010, 47:153-161.
40. Ruef C., Coleman D.L. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990, 12:41-62.
41. Vlassara H., Striker G.E. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011.
42. Howes K.A., Liu Y., Dunaief J.L., Milam A., Frederick J.M., Marks A., et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 2004, 45:3713-3720.
43. Lu C., He J.C., Cai W., Liu H., Zhu L., Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. PNAS 2004, 101:11767-11772.
44. Sourris K.C., Forbes J.M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr Drug Targets 2009, 10:42-50.
45. Vlassara H., Uribarri J., Cai W., Striker G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann NY Acad Sci 2008, 1126:46-52.
46. Yamada Y., Ishibashi K., Bhutto I.A., Tian J., Lutty G.A., Handa J.T. The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp Eye Res 2006, 82:840-848.
47. Ahn K.S., Aggarwal B.B. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005, 1056:218-233.
48. Crane I.J., Wallace C.A., Forrester J.V. Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-1beta and IFN-gamma. Cell Immunol 2001, 209:132-139.
49. Yang C.H., Wei L., Pfeffer S.R., Du Z., Murti A., Valentine W.J., et al. Identification of CXCL11 as a STAT3-dependent gene induced by IFN. J Immunol 2007, 178:986-992.
50. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 2010, 16:1107-1111.
51. Arend W.P., Malyak M., Guthridge C.J., Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27-55.
52. Fichorova R.N., Lai J.J., Schwartz J.L., Weiner D.H., Mauck C.K., Callahan M.M. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. Cytokine 2011, 55:134-140.
53. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6:232-241.
54. Demoulin J.B., Renauld J.C. Interleukin 9 and its receptor: an overview of structure and function. Int Rev Immunol 1998, 16:345-364.
55. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 2003, 21:425-456.
56. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
57. Xu H., Chen M., Forrester J.V. Para-inflammation in the aging retina. Prog Retin Eye Res 2009, 28:348-368.
58. Jiang K, Cao S, Cui JZ, Matsubara JA. Immuno-modulatory effect of IFN-gamma in AMD and its role as a possible target for therapy. J Clin Exp Ophthalmol 2012;S2. Review. in press.
59. Chen H., Liu B., Lukas T.J., Neufeld A.H. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS One 2008, 3:e2339.
60. Chen M., Forrester J.V., Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp Eye Res 2007, 84:635-645.
61. Spencer K.L., Olson L.M., Schnetz-Boutaud N., Gallins P., Agarwal A., Iannaccone A., et al. Using genetic variation and environmental risk factor data to identify individuals at high risk for age-related macular degeneration. PLoS One 2011, 6:e17784.
62. Cui J., Kurji K., Lin T.K., Prasad S., Kojic L., Matsubara J.A. Microarray-based gene set analysis: pathway analysis of advanced glycation endproduct (AGEs) or amyloid beta (A{beta}) stimulation of human RPE in vitro. Invest Ophthalmol Vis Sci 2009, 50. 707-D61.
63. Holtkamp G.M., Kijlstra A., Peek R., de Vos A.F. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 2001, 20:29-48.
64. Ma W., Zhao L., Fontainhas A.M., Fariss R.N., Wong W.T. Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD. PLoS One 2009, 4:e7945.
65. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695-708.
66. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.